A novel spectrophotometric method for the determination of voglibose in pharmaceuticals using potassium ferricyanide-Fe (III) as chromogenic agent
Department of Pharmaceutical Analysis, Pydah College of Pharmacy, Kakinada, Andhra Pradesh- 533461, India.
Research Article
GSC Biological and Pharmaceutical Sciences, 2024, 28(01), 043–053.
Article DOI: 10.30574/gscbps.2024.28.1.0246
Publication history:
Received on 13 May 2024; revised on 02 July 2024; accepted on 05 July 2024
Abstract:
The following research presents a simple, fast, accurate and sensitive visible spectrophotometric method for the estimation of voglibose using potassium ferricyanide-Fe(III) as a reagent. It was determined that a reduction to Fe(II) was carried out from Fe(III) using voglibose with the formation of a Prussian blue colored solution as K-Fe (III) [Fe (II) (CN)6] in which the λmax was found at 775 nm. To verify the analytical approach, i.e. simplicity, accuracy, precision, LOD and LOQ , a study was conducted from the parameters established according to the ICH guideline. Drug exhibited distinct λmax in Ferric chloride, Potassium ferricyanide at 775 nm. Linearity was observed with a 1-5 µg/mL range of concentration with correlation coefficient (r2) 0.999.The estimated amount of drug in tablets is in good-agreement as per the claims written on the label. This technique is statistically validated as well as the recovery percentage of the drug by visible spectrophotometric method was found to be 98.5%-100.7%. The proposed methodology followed to estimate the Voglibose in bulk and dosage form in tablet is economical and sensitive.
Keywords:
Voglibose; Ferric chloride; Potassium ferricyanide; Visible-Spectrophotometric method
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
